US2183521028
US2183521028
Corcept Therapeutics Incorporat
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 13.1B EUR | 9.38B EUR | 4.33B EUR | 3.69B EUR |
Enterprise Value | 12.52B EUR | 9.28B EUR | 4.23B EUR | 3.57B EUR |
Valuation Multiples | ||||
Trailing P/E | 269.31x | 170.05x | 91.38x | 46.62x |
Forward P/E | 27.53x | -- | -- | -- |
Price to Sales | 15.77x | 11.29x | 5.63x | 6.1x |
Price to Book | 18.53x | 13.3x | 6.78x | 5.69x |
EV/Revenue | 15.06x | 11.17x | 5.5x | 5.91x |
EV/EBITDA | 1,548.15x | 1,051.8x | -- | 83.47x |
Price to FCF (P/FCF) | 169.27x | 87.76x | 36.01x | 26.89x |
EV/FCF | 161.71x | 86.81x | 35.18x | 26.06x |
FCF Yield | 0.59% | 1.14% | 2.78% | 3.72% |